138 related articles for article (PubMed ID: 802977)
21. Voice quality severity and responsiveness to levodopa in Parkinson's disease.
Cushnie-Sparrow D; Adams S; Abeyesekera A; Pieterman M; Gilmore G; Jog M
J Commun Disord; 2018; 76():1-10. PubMed ID: 30053648
[TBL] [Abstract][Full Text] [Related]
22. Speech rate in Parkinson's disease: A controlled study.
Martínez-Sánchez F; Meilán JJ; Carro J; Gómez Íñiguez C; Millian-Morell L; Pujante Valverde IM; López-Alburquerque T; López DE
Neurologia; 2016 Sep; 31(7):466-72. PubMed ID: 25660139
[TBL] [Abstract][Full Text] [Related]
23. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
Paul R; Borah A
Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
[TBL] [Abstract][Full Text] [Related]
24. The effect of L-dopa treatment on the speech of patients with Parkinson's disease.
Audelman JU; Hoel RL; Lassman FM
Neurology; 1970 Apr; 20(4):410-1. PubMed ID: 5535064
[No Abstract] [Full Text] [Related]
25. Impact of Parkinson's disease and levodopa on resting state functional connectivity related to speech prosody control.
Elfmarková N; Gajdoš M; Mračková M; Mekyska J; Mikl M; Rektorová I
Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S52-5. PubMed ID: 26363673
[TBL] [Abstract][Full Text] [Related]
26. [Speech and voice disorders in Parkinson's disease].
Martnez-Sánchez F
Rev Neurol; 2010 Nov; 51(9):542-50. PubMed ID: 20979034
[TBL] [Abstract][Full Text] [Related]
27. Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease.
Chen H; Fang J; Li F; Gao L; Feng T
Neurol Sci; 2015 Jul; 36(7):1217-23. PubMed ID: 25616444
[TBL] [Abstract][Full Text] [Related]
28. [Results of short and long-term treatment of parkinsonism with L-dopa].
Domzal T; Pakszys W; Domzal B; Ligezińska B
Neurol Neurochir Pol; 1976; 10(5):637-43. PubMed ID: 980203
[TBL] [Abstract][Full Text] [Related]
29. L-dopa and the secretion of sebum in Parkinsonian patients.
Streifler M; Avrami E; Rabey JM
Eur Neurol; 1980; 19(1):43-8. PubMed ID: 7371653
[TBL] [Abstract][Full Text] [Related]
30. Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study.
Tykalová T; Rusz J; Čmejla R; Klempíř J; Růžičková H; Roth J; Růžička E
J Neural Transm (Vienna); 2015 Aug; 122(8):1135-42. PubMed ID: 25583417
[TBL] [Abstract][Full Text] [Related]
31. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
[TBL] [Abstract][Full Text] [Related]
32. The Bereitschaftspotential, L-DOPA and Parkinson's disease.
Dick JP; Cantello R; Buruma O; Gioux M; Benecke R; Day BL; Rothwell JC; Thompson PD; Marsden CD
Electroencephalogr Clin Neurophysiol; 1987 Mar; 66(3):263-74. PubMed ID: 2434310
[TBL] [Abstract][Full Text] [Related]
33. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa.
Fertl E; Auff E; Doppelbauer A; Waldhauser F
J Neural Transm Park Dis Dement Sect; 1993; 5(3):227-34. PubMed ID: 8369102
[TBL] [Abstract][Full Text] [Related]
34. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
LeWitt PA
Mov Disord; 2015 Jan; 30(1):64-72. PubMed ID: 25449210
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
36. Impairment of somatosensory feedback control of the tongue in Parkinson's disease: effect of L-Dopa therapy.
Sandyk R; Brennan MJ
S Afr J Commun Disord; 1982; 29():49-54. PubMed ID: 7186204
[No Abstract] [Full Text] [Related]
37. Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.
Muenter MD; Sharpless NS; Tyce GM; Darley FL
Mayo Clin Proc; 1977 Mar; 52(3):163-74. PubMed ID: 839864
[TBL] [Abstract][Full Text] [Related]
38. Variations in axial, proximal, and distal motor response to L-dopa in multisystem atrophy and Parkinson's disease.
Fetoni V; Genitrini S; Monza D; Soliveri P; Testa D; Caraceni T; Girotti F
Clin Neuropharmacol; 1997 Jun; 20(3):239-44. PubMed ID: 9197947
[TBL] [Abstract][Full Text] [Related]
39. Juvenile Parkinson's disease and its response to L-dopa therapy.
Askenasy JJ; Mendelson L; Keren O; Braun Z
J Neural Transm Park Dis Dement Sect; 1990; 2(1):23-30. PubMed ID: 2357269
[TBL] [Abstract][Full Text] [Related]
40. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
